rifai podcasts

Episode 324: Syria's Shifting Identity and Political Landscape with Ola Rifai

Play Episode Listen Later Feb 15, 2026 29:15 Transcription Available

In this episode of the International Risk Podcast, Dominic Bowen speaks with Dr Ola Rifai about the evolution of Syrian identity and how competing narratives of nationalism, sectarianism, and statehood have shaped the country's political trajectory before and after 2011.Find out more about how identity was managed under the Assad regime, how sectarianisation unfolded differently in cities such as Homs and Damascus, and why collective memory, displacement, and institutional weakness continue to influence Syria's fragile post-conflict landscape.The conversation also examines citizenship, state formation, and the structural challenges of rebuilding trust between communities after prolonged violence. Dr Rifai explores whether a unified Syrian national identity can be reconstructed, and what role education, transitional justice, and institutional reform will play in that process.Finally, they discuss the regional and geopolitical dimensions of Syria's transformation, the risks posed by unresolved identity fractures, and the indicators policymakers and risk professionals should monitor as Syria navigates its next phase.Tell us what you liked!

identity shifting syria syrian damascus assad identity politics political landscape homs conflict analysis rifai

Dr. Tom Rifai on the Flex5 Food Pyramid

The Paul W. Smith Show

Play Episode Listen Later Jan 20, 2026 8:12

January 20, 2026 ~ Dr. Tom Rifai, President and CEO Reality Meets Science Inc. Past President US National Board of Physician Nutrition Specialists discusses the new food pyramid, what they got wrong and what they missed. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

president simplecast food pyramid rifai physician nutrition specialists

#91: Farmacología en neurorrehabilitación del adulto

Hemispherics

Play Episode Listen Later Jan 17, 2026 102:38

En este episodio abordo la farmacología en neurorrehabilitación del adulto desde una perspectiva clínica y realista, pensada especialmente para profesionales no médicos que conviven a diario con informes, pautas y nombres de fármacos sin disponer siempre de un marco claro para interpretarlos. Recorremos los principales medicamentos utilizados en patologías neurológicas frecuentes —ictus, lesión medular, esclerosis múltiple, enfermedad de Parkinson, ELA, distonías y traumatismo craneoencefálico— diferenciando entre tratamientos agudos, terapias modificadoras de la enfermedad y manejo farmacológico de secuelas. A lo largo del episodio explico de forma progresiva los mecanismos de acción, la base neurofisiológica y el estado actual de la evidencia, poniendo especial énfasis en qué fármacos realmente cambian el pronóstico y cuáles cumplen un papel fundamentalmente sintomático. El objetivo no es prescribir, sino entender mejor cómo la farmacología condiciona la recuperación, la participación en terapia y la toma de decisiones en neurorrehabilitación, con una mirada crítica y basada en la evidencia disponible. Referencias del episodio: 1. Adams, M. M., & Hicks, A. L. (2005). Spasticity after spinal cord injury. Spinal cord, 43(10), 577–586. https://doi.org/10.1038/sj.sc.3101757 (https://pubmed.ncbi.nlm.nih.gov/15838527/). 2. AFFINITY Trial Collaboration (2020). Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. The Lancet. Neurology, 19(8), 651–660. https://doi.org/10.1016/S1474-4422(20)30207-6 (https://pubmed.ncbi.nlm.nih.gov/32702334/). 3. Angeli, C. A., Edgerton, V. R., Gerasimenko, Y. P., & Harkema, S. J. (2014). Altering spinal cord excitability enables voluntary movements after chronic complete paralysis in humans. Brain : a journal of neurology, 137(Pt 5), 1394–1409. https://doi.org/10.1093/brain/awu038 (https://pubmed.ncbi.nlm.nih.gov/24713270/). 4. Bracken, M. B., Shepard, M. J., Collins, W. F., Holford, T. R., Young, W., Baskin, D. S., Eisenberg, H. M., Flamm, E., Leo-Summers, L., & Maroon, J. (1990). A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. The New England journal of medicine, 322(20), 1405–1411. https://doi.org/10.1056/NEJM199005173222001 (https://pubmed.ncbi.nlm.nih.gov/2278545/). 5. Bracken, M. B., Shepard, M. J., Holford, T. R., Leo-Summers, L., Aldrich, E. F., Fazl, M., Fehlings, M., Herr, D. L., Hitchon, P. W., Marshall, L. F., Nockels, R. P., Pascale, V., Perot, P. L., Jr, Piepmeier, J., Sonntag, V. K., Wagner, F., Wilberger, J. E., Winn, H. R., & Young, W. (1997). Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA, 277(20), 1597–1604 (https://pubmed.ncbi.nlm.nih.gov/9168289/). 6. Cardenas, D. D., Ditunno, J. F., Graziani, V., McLain, A. B., Lammertse, D. P., Potter, P. J., Alexander, M. S., Cohen, R., & Blight, A. R. (2014). Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury. Spinal cord, 52(1), 70–76. https://doi.org/10.1038/sc.2013.137 (https://pubmed.ncbi.nlm.nih.gov/24216616/). 7. Chollet, F., Tardy, J., Albucher, J. F., Thalamas, C., Berard, E., Lamy, C., Bejot, Y., Deltour, S., Jaillard, A., Niclot, P., Guillon, B., Moulin, T., Marque, P., Pariente, J., Arnaud, C., & Loubinoux, I. (2011). Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. The Lancet. Neurology, 10(2), 123–130. https://doi.org/10.1016/S1474-4422(10)70314-8 (https://pubmed.ncbi.nlm.nih.gov/21216670/). 8. Dávalos, A., Alvarez-Sabín, J., Castillo, J., Díez-Tejedor, E., Ferro, J., Martínez-Vila, E., Serena, J., Segura, T., Cruz, V. T., Masjuan, J., Cobo, E., Secades, J. J., & International Citicoline Trial on acUte Stroke (ICTUS) trial investigators (2012). Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet (London, England), 380(9839), 349–357. https://doi.org/10.1016/S0140-6736(12)60813-7 (https://pubmed.ncbi.nlm.nih.gov/22691567/). 9. EFFECTS Trial Collaboration (2020). Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. The Lancet. Neurology, 19(8), 661–669. https://doi.org/10.1016/S1474-4422(20)30219-2 (https://pubmed.ncbi.nlm.nih.gov/32702335/). 10. Fehlings, M. G., Theodore, N., Harrop, J., Maurais, G., Kuntz, C., Shaffrey, C. I., Kwon, B. K., Chapman, J., Yee, A., Tighe, A., & McKerracher, L. (2011). A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. Journal of neurotrauma, 28(5), 787–796. https://doi.org/10.1089/neu.2011.1765 (https://pubmed.ncbi.nlm.nih.gov/21381984/). 11. FOCUS Trial Collaboration (2019). Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet (London, England), 393(10168), 265–274. https://doi.org/10.1016/S0140-6736(18)32823-X (https://pubmed.ncbi.nlm.nih.gov/30528472/). 12. Forgione, N., & Fehlings, M. G. (2014). Rho-ROCK inhibition in the treatment of spinal cord injury. World neurosurgery, 82(3-4), e535–e539. https://doi.org/10.1016/j.wneu.2013.01.009 (http://pubmed.ncbi.nlm.nih.gov/23298675/). 13. Fournier, A. E., Takizawa, B. T., & Strittmatter, S. M. (2003). Rho kinase inhibition enhances axonal regeneration in the injured CNS. The Journal of neuroscience : the official journal of the Society for Neuroscience, 23(4), 1416–1423. https://doi.org/10.1523/JNEUROSCI.23-04-01416.2003 (https://pubmed.ncbi.nlm.nih.gov/12598630/). 14. Giacino, J. T., Whyte, J., Bagiella, E., Kalmar, K., Childs, N., Khademi, A., Eifert, B., Long, D., Katz, D. I., Cho, S., Yablon, S. A., Luther, M., Hammond, F. M., Nordenbo, A., Novak, P., Mercer, W., Maurer-Karattup, P., & Sherer, M. (2012). Placebo-controlled trial of amantadine for severe traumatic brain injury. The New England journal of medicine, 366(9), 819–826. https://doi.org/10.1056/NEJMoa1102609 (https://pubmed.ncbi.nlm.nih.gov/22375973/). 15. Goodman, A. D., Brown, T. R., Krupp, L. B., Schapiro, R. T., Schwid, S. R., Cohen, R., Marinucci, L. N., Blight, A. R., & Fampridine MS-F203 Investigators (2009). Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet (London, England), 373(9665), 732–738. https://doi.org/10.1016/S0140-6736(09)60442-6 (https://pubmed.ncbi.nlm.nih.gov/19249634/). 16. Goodman, A. D., Brown, T. R., Edwards, K. R., Krupp, L. B., Schapiro, R. T., Cohen, R., Marinucci, L. N., Blight, A. R., & MSF204 Investigators (2010). A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of neurology, 68(4), 494–502. https://doi.org/10.1002/ana.22240 (https://pubmed.ncbi.nlm.nih.gov/20976768/). 17. Hurlbert, R. J., Hadley, M. N., Walters, B. C., Aarabi, B., Dhall, S. S., Gelb, D. E., Rozzelle, C. J., Ryken, T. C., & Theodore, N. (2013). Pharmacological therapy for acute spinal cord injury. Neurosurgery, 72 Suppl 2, 93–105. https://doi.org/10.1227/NEU.0b013e31827765c6 (https://pubmed.ncbi.nlm.nih.gov/23417182/). 18. Johnston, S. C., Amarenco, P., Denison, H., Evans, S. R., Himmelmann, A., James, S., Knutsson, M., Ladenvall, P., Molina, C. A., Wang, Y., & THALES Investigators (2020). Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. The New England journal of medicine, 383(3), 207–217. https://doi.org/10.1056/NEJMoa1916870 (https://pubmed.ncbi.nlm.nih.gov/32668111/). 19. Kheder, A., & Nair, K. P. (2012). Spasticity: pathophysiology, evaluation and management. Practical neurology, 12(5), 289–298. https://doi.org/10.1136/practneurol-2011-000155 (https://pubmed.ncbi.nlm.nih.gov/22976059/). 20. Kirkman, M. A., Day, J., Gehring, K., Zienius, K., Grosshans, D., Taphoorn, M., Li, J., & Brown, P. D. (2022). Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. The Cochrane database of systematic reviews, 11(11), CD011335. https://doi.org/10.1002/14651858.CD011335.pub3 (https://pubmed.ncbi.nlm.nih.gov/36427235/). 21. Martinsson L, Hårdemark H, Eksborg S. Amphetamines for improving recovery after stroke. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD002090. doi: 10.1002/14651858.CD002090.pub2. PMID: 17253474; PMCID: PMC12278358 (https://pubmed.ncbi.nlm.nih.gov/17253474/). 22. Miller, T. M., Cudkowicz, M. E., Genge, A., Shaw, P. J., Sobue, G., Bucelli, R. C., Chiò, A., Van Damme, P., Ludolph, A. C., Glass, J. D., Andrews, J. A., Babu, S., Benatar, M., McDermott, C. J., Cochrane, T., Chary, S., Chew, S., Zhu, H., Wu, F., Nestorov, I., … VALOR and OLE Working Group (2022). Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. The New England journal of medicine, 387(12), 1099–1110. https://doi.org/10.1056/NEJMoa2204705 (https://pubmed.ncbi.nlm.nih.gov/36129998/). 23. Mueller, B. K., Mack, H., & Teusch, N. (2005). Rho kinase, a promising drug target for neurological disorders. Nature reviews. Drug discovery, 4(5), 387–398. https://doi.org/10.1038/nrd1719 (https://pubmed.ncbi.nlm.nih.gov/15864268/). 24. Nourbakhsh, B., Revirajan, N., & Waubant, E. (2018). Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. Contemporary clinical trials, 64, 67–76. https://doi.org/10.1016/j.cct.2017.11.005 (https://pubmed.ncbi.nlm.nih.gov/29113955/). 25. Paganoni, S., Hendrix, S., Dickson, S. P., Knowlton, N., Macklin, E. A., Berry, J. D., Elliott, M. A., Maiser, S., Karam, C., Caress, J. B., Owegi, M. A., Quick, A., Wymer, J., Goutman, S. A., Heitzman, D., Heiman-Patterson, T. D., Jackson, C. E., Quinn, C., Rothstein, J. D., Kasarskis, E. J., … Cudkowicz, M. E. (2021). Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle & nerve, 63(1), 31–39. https://doi.org/10.1002/mus.27091 (https://pubmed.ncbi.nlm.nih.gov/33063909/). 26. Schwab M. E. (2004). Nogo and axon regeneration. Current opinion in neurobiology, 14(1), 118–124. https://doi.org/10.1016/j.conb.2004.01.004 (https://pubmed.ncbi.nlm.nih.gov/15018947/). 27. Shneider, N. A., Harms, M. B., Korobeynikov, V. A., Rifai, O. M., Hoover, B. N., Harrington, E. A., Aziz-Zaman, S., Singleton, J., Jamil, A., Madan, V. R., Lee, I., Andrews, J. A., Smiley, R. M., Alam, M. M., Black, L. E., Shin, M., Watts, J. K., Walk, D., Newman, D., Pascuzzi, R. M., … Bennett, C. F. (2025). Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series. Lancet (London, England), 405(10494), 2075–2086. https://doi.org/10.1016/S0140-6736(25)00513-6 (https://pubmed.ncbi.nlm.nih.gov/40414239/). 28. Stocchi, F., Bravi, D., Emmi, A., & Antonini, A. (2024). Parkinson disease therapy: current strategies and future research priorities. Nature reviews. Neurology, 20(12), 695–707. https://doi.org/10.1038/s41582-024-01034-x (https://pubmed.ncbi.nlm.nih.gov/39496848/).

black world england child young walk nature society brain focus safety current trial journal practical treatments effects new england glass adams sr drug neuroscience mart evans results edwards parkinson wagner muscle shaw administration valor li newman andrews flame ela goodman watts chapman johnston luther castillo wang contemporary mueller katz hicks herr hammond neurology molina vila walters mercer placebos hoover maroon chew segura tia interventions novak harrington shin jean claude van damme sustained neu arnaud lancet wu jama smiley cho ferro harms mcdermott dickson no go singleton marque cns affinity adulto spinal cochrane fournier pascale whyte alam baskin altering winn annals nair eisenberg centaurs jamil aspirin neurosurgery blight pmid gelb cardenas kwon suppl yee moulin zhu babu aldrich angeli rothstein karam denison referencias kalmar bracken recorremos mclain kirkman tardy kuntz macklin madan knowlton cobo tighe lamy rho krupp amphetamines edgerton caress pharmacological ictus bravi gehring sherer schapiro perot antonini berard benatar graziani chollet tejedor guillon ryken farmacolog eifert flamm cochrane database syst rev knutsson spasticity acute ischemic stroke rifai chary marinucci antisense holford ticagrelor fluoxetine jneurosci maurais deltour s1474 gerasimenko

Interview with Dr. Muhamad Aly Rifai, CEO & Chief Psychiatrist and Internist of Blue Mountain Psychiatry

Influential Entrepreneurs with Mike Saunders, MBA

Play Episode Listen Later Nov 13, 2025 18:22

Dr. Muhamad Aly Rifai is a highly respected internist and psychiatrist serving the Greater Lehigh Valley, Pennsylvania. As the CEO and Chief Psychiatrist and Internist of Blue Mountain Psychiatry, he leads with expertise and dedication to mental health and internal medicine. He also holds the distinguished title of Lehigh Valley Endowed Chair of Addiction Medicine, further solidifying his authority in the field.Dr. Rifai is Board Certified in multiple specialties, including Internal Medicine, Psychiatry, Addiction Medicine, and Psychosomatic Medicine, demonstrating his extensive knowledge and commitment to comprehensive patient care. His professional achievements have earned him recognition as a Fellow of the American College of Physicians, the Academy of Psychosomatic Medicine, and the American Psychiatric Association. Additionally, he has served as the President of the Lehigh Valley Psychiatric Society, contributing significantly to the advancement of psychiatric practice in the region.Learn more: http://www.alyrifai.com/Influential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-with-dr-muhamad-aly-rifai-ceo-chief-psychiatrist-and-internist-of-blue-mountain-psychiatry

ceo president pennsylvania chief academy fellow physicians psychiatry american colleges psychiatrist internal medicine board certified american psychiatric association addiction medicine internist blue mountain muhamad mike saunders psychosomatic medicine rifai mike saundershttps

Interview with Dr. Muhamad Aly Rifai, CEO & Chief Psychiatrist and Internist of Blue Mountain Psychiatry

Business Innovators Radio

Play Episode Listen Later Nov 13, 2025 18:22

Dr. Muhamad Aly Rifai is a highly respected internist and psychiatrist serving the Greater Lehigh Valley, Pennsylvania. As the CEO and Chief Psychiatrist and Internist of Blue Mountain Psychiatry, he leads with expertise and dedication to mental health and internal medicine. He also holds the distinguished title of Lehigh Valley Endowed Chair of Addiction Medicine, further solidifying his authority in the field.Dr. Rifai is Board Certified in multiple specialties, including Internal Medicine, Psychiatry, Addiction Medicine, and Psychosomatic Medicine, demonstrating his extensive knowledge and commitment to comprehensive patient care. His professional achievements have earned him recognition as a Fellow of the American College of Physicians, the Academy of Psychosomatic Medicine, and the American Psychiatric Association. Additionally, he has served as the President of the Lehigh Valley Psychiatric Society, contributing significantly to the advancement of psychiatric practice in the region.Learn more: http://www.alyrifai.com/Influential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-with-dr-muhamad-aly-rifai-ceo-chief-psychiatrist-and-internist-of-blue-mountain-psychiatry

ceo president pennsylvania chief academy fellow physicians psychiatry american colleges psychiatrist internal medicine board certified american psychiatric association addiction medicine internist blue mountain muhamad mike saunders psychosomatic medicine rifai mike saundershttps

DENISE RIFAI: "TARA NU SE LASA MOSTENIRE!" VIN DE-O POVESTE by RADU TIBULCA

Vin de-o poveste

Play Episode Listen Later Nov 13, 2025 93:16

Denise Rifai vine la o poveste alături de mine. Povestim despre începuturile proiectului "40 de întrebări", ce a făcut-o să plece de la Realitatea, cum înțeleg românii politica, de ce n-ar trebui ca funcțiile de conducere să se lase moștenire, cât de important este votul românilor și cât de mult îi sperie pe politicieni, care au fost cei mai incomozi invitați la "40", ce a dus la apariția proiectului "În oglindă" cu foștii candidați la prezidențiale și multe, multe altele.

radu lasa rifai poveste povestim

Surviving War, Cancer, and the DOJ: The Resilient Dr. Rifai

Nightmare Success In and Out

Play Episode Listen Later Aug 14, 2025 59:10

In this episode of Nightmare Success, Brent Cassity interviews Dr. Muhamad Ali Rifai, who shares his incredible journey from surviving a war-torn childhood in Syria to facing a federal investigation in the United States. Dr. Rafi survived machine gun fire as a child. He escaped thyroid cancer and a car crash that should have killed him, but nothing prepared him for going to trial with the United States Government. The Doctor discusses his experiences with raw authenticity, the challenges of navigating the legal system, and the importance of telemedicine. Dr. Rifai, who is both an internist and psychiatrist, was a pioneer of telemedicine. He emphasizes the need for professionals to understand the complexities of the law and shares insights from his own trial, where he was ultimately acquitted of all charges. His big "tip" is do not talk to the investigators, they are professionals. Let your attorney handle all communications. The conversation highlights the power of staying true to your beliefs and the importance of supporting others in similar situations. Dr. Rifai is the author of the book Doctor Not Guilty, and he is the founder of SHIELD that helps professionals through the complicated process of being indicted. Show sponsors: Navigating the challenges of white-collar crime? The White-Collar Support Group at Prisonist.org offers guidance, resources, and a community for those affected. Discover support today at Prisonist.org Protect your online reputation with Discoverability! Use code NIGHTMARE SUCCESS for an exclusive discount on services to boost your digital image and online reputation. Visit Discoverability.co and secure your online presence today. Skip the hassle of car shopping with Auto Plaza Direct. They'll handle every detail to find your perfect vehicle. Visit AutoPlazaDirect.com "Your personal car concierge!"

united states discover navigating doctors cancer surviving protect syria skip shield resilient rafi united states government not guilty discoverability rifai brent cassity nightmare success

Addressing America's reliance on psychotropic medication

The Podcast by KevinMD

Play Episode Listen Later May 18, 2025 18:19

Practicing internist and psychiatrist Muhamad Aly Rifai discusses his article, "How America became overmedicated—and what we can do about it." He raises concerns about the high rate of psychotropic medication use in the U.S., citing CDC data suggesting nearly 1 in 4 adults may be taking these drugs, often without clear long-term plans or exit strategies. Muhamad contrasts this with U.K. NICE guidelines that emphasize structured deprescribing protocols, highlighting a significant gap in U.S. clinical guidance. He points to systemic issues like short medication management visits, lack of industry incentives for deprescribing, and the need for better physician training in distinguishing withdrawal symptoms from relapse. Dr. Rifai advocates for a national shift towards wellness, emphasizing medication optimization, integrated behavioral health (including therapy and trauma-informed care), addressing social determinants of health, and fostering recovery-oriented conversations that explore non-pharmacologic approaches like peer support, nutrition, and exercise. Actionable takeaways include the need for robust deprescribing guidelines, investment in holistic and integrated care models, and a conscious effort by clinicians to discuss not just starting medications, but also safely stopping them when appropriate. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise—and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

america ai healthcare addressing practicing cdc medications actionable reliance microsoft cloud muhamad psychotropic rifai

DOJ vs. Doctor: One Physician's Victory

Doctors and Litigation: The L Word

Play Episode Listen Later May 17, 2025 27:39

Following up after episode 15, "What to Know When the Government Comes Knocking," Dr. Pensa interviews a physician who went up against the US Department of Justice -- and won. Dr. Muhamad Aly Rifai is a practicing psychiatrist, boarded in psychiatry and internal medicine, who was indicted on charges of healthcare fraud by the US government in 2022, following seven years of investigation. Dr. Rifai was confident he was innocent, and confident in his billing practices -- and despite intimidation by the government, threats of imprisonment for up to 40 years, and very long odds, he refused to settle. He won against the US Government after a 6-day trial, and is here to share what he learned in his ordeal. This Department of Justice press release describes the accusations against Dr. Rifai. (I feel they should update the headline!) After demonstrating that the case was baseless and should never have been brought to trial in the first place, along with his resounding victory in court, Dr. Rifai filed a motion for sanctions and to recoup his substantial legal fees. In the wake of that motion, one prosecuting attorney was fired, and two others have 'retired.' The motion, as of May 2025, is still in limbo. Dr. Rifai shares his story in an effort to educate all of us, and to empower physicians going through similar circumstances.

doctors victory physicians us department us government pensa rifai

Podcasts about rifai

Best podcasts about rifai

Muhammadan Way

Learn About Islam

The Paul W. Smith Show

Heard Tell

DealMakers

Dispatch with Sergio Jordann

True Health Revealed

Ã‚min-YÃ¢-Rabbi

Travelnews Online | Rebuilding Travel | Trending | eTurboNews

Latest news about rifai

Latest podcast episodes about rifai

Episode 324: Syria's Shifting Identity and Political Landscape with Ola Rifai

Dr. Tom Rifai on the Flex5 Food Pyramid

#91: Farmacología en neurorrehabilitación del adulto

Interview with Dr. Muhamad Aly Rifai, CEO & Chief Psychiatrist and Internist of Blue Mountain Psychiatry

Interview with Dr. Muhamad Aly Rifai, CEO & Chief Psychiatrist and Internist of Blue Mountain Psychiatry

DENISE RIFAI: "TARA NU SE LASA MOSTENIRE!" VIN DE-O POVESTE by RADU TIBULCA

Surviving War, Cancer, and the DOJ: The Resilient Dr. Rifai

Addressing America's reliance on psychotropic medication

DOJ vs. Doctor: One Physician's Victory

Ya Mustafa saw Ali Uthman New English Nasheed Mystic Meditation

Fasting With Your Senses to Unlock New Quran Understandings

My Throne is Upon Water Understanding Gods Symbolic Message

True Growth Comes From Service to the Shaykhs Mission Not Pondering about Surah Ya Seen All Day

There Are No Laws of Physics Theres Only the Landscape

Modern Day Crooked Islam Her Dress Code Has Become His Only Virtue

Afdalul Alamin Sultan New English Nasheed Mystic Meditation

Deep Secret Discovery They Found Real Life Fallen Angels

What Did Angel Gabriel as See When Receiving Knowledge

Muhammadan Paradise saw Layla Zahra New English Nasheed Mystic Meditation

Asadullah Muhammad Ali Khan New English Nasheed Mystic Meditation

15th Shaban Wazifa 3x Surah Yasin and Dua

Ilm Huroof Analysis of the Word Masjid

Ahl Badr 313 Sultan New Ramadan Nasheed Mystic Meditation

We Praise Muhammad Layla Zahra 2025 Ramadan Nasheed Mystic Meditation

Dragons Sultan New Ramadan Nasheed Mystic Meditation

Mawla Ali Jan Bilal Reggae New Ramadan Nasheed Mystic Meditation

Ya Nabi Ali Uthman New Ramadan Nasheed Mystic Meditation

Organic Prayer Why Natural Fibers Are Better for Grounding Energy in Salah

Bonus Podcast: Improving Your Metabolic Health with Expert Tom Rifai, MD

Life Moves Fast Stop Sometimes to See the Subtle Signs

Gul e Muhammadi saw Layla Zahra New Ramadan Nasheed Mystic Meditation

El Intercesor Umar Gonzalez New Ramadan Nasheed Mystic Meditation

Prophet Muhammad Peace Be Upon You Layla Zahra New Ramadan Nasheed Mystic Meditation

I Dont Know Akhi Khalifa New Nasheed Mystic Meditation

All Things Bow Onto Thee Will Allah Make Kaaba The Tallest Building

Khalifa Himmah GET UP New Ramadan Nasheed Mystic Meditation

Hadith Revisited Hearts Not Bricks Earns Houses in Paradise

John Wadud A Mercy For All New Ramadan Nasheed Mystic Meditation

Sultan Ramadan Mubarak New Ramadan Nasheed 2025 Mystic Meditation

Soul Ties and Quantum Entanglement

Sultan Lasers New Ramadan Nasheed Mystic Meditation

In Search of Allahs Endless Treasures

Why are 4 Prophets Still Physically Alive

Qareen Satans Spy on You The Hidden Source Behind Psychic Readings

Jinn Humanoids Jinn DNA Many Creations Out There

Sultan Days of Rahmah New Ramadan Nasheed Mystic Meditation

Chor Fikr Dunya Ki New Ramadan Naat English Translation Mystic Meditation

Malik Naqshi Light Upon Light New Ramadan Nasheed Mystic Meditation

Bilal Reggae One Nur One Haqq New Ramadan Nasheed Mystic Meditation

Idol Worship in Disguise When They Mistake Stones for the House of Allah